{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Bender O"],"funding":["University of Hail"],"pagination":["6968-6981"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9948168"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["8(7)"],"pubmed_abstract":["The structure-based design introduced indoles as an essential motif in designing new selective estrogen receptor modulators employed for treating breast cancer. Therefore, here, a series of synthesized vanillin-substituted indolin-2-ones were screened against the NCI-60 cancer cell panel followed by in vivo, in vitro, and in silico studies. Physicochemical parameters were evaluated with HPLC and SwissADME tools. The compounds demonstrated promising anti-cancer activity for the MCF-7 breast cancer cell line (GI = 6-63%). The compound with the highest activity (<b>6j</b>) was selective for the MCF-7 breast cancer cell line (IC<sub>50</sub> = 17.01 μM) with no effect on the MCF-12A normal breast cell line supported by real-time cell analysis. A morphological examination of the used cell lines"],"journal":["ACS omega"],"pubmed_title":["Vanillin-Based Indolin-2-one Derivative Bearing a Pyridyl Moiety as a Promising Anti-Breast Cancer Agent via Anti-Estrogenic Activity."],"pmcid":["PMC9948168"],"funding_grant_id":["RG-21 131"],"pubmed_authors":["Shawky AM","Awad EM","Ali TFS","Anwar S","Celik I","Mohamed M","Dogan R","Ahmed AF","Atalay A","Younes KM","Alaaeldin E","Ansari M","Bender O","Beshr EAM","Shoman ME"],"additional_accession":[]},"is_claimable":false,"name":"Vanillin-Based Indolin-2-one Derivative Bearing a Pyridyl Moiety as a Promising Anti-Breast Cancer Agent via Anti-Estrogenic Activity.","description":"The structure-based design introduced indoles as an essential motif in designing new selective estrogen receptor modulators employed for treating breast cancer. Therefore, here, a series of synthesized vanillin-substituted indolin-2-ones were screened against the NCI-60 cancer cell panel followed by in vivo, in vitro, and in silico studies. Physicochemical parameters were evaluated with HPLC and SwissADME tools. The compounds demonstrated promising anti-cancer activity for the MCF-7 breast cancer cell line (GI = 6-63%). The compound with the highest activity (<b>6j</b>) was selective for the MCF-7 breast cancer cell line (IC<sub>50</sub> = 17.01 μM) with no effect on the MCF-12A normal breast cell line supported by real-time cell analysis. A morphological examination of the used cell lines","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2026-04-08T14:23:40.442Z","creation":"2024-11-12T18:06:37.491Z"},"accession":"S-EPMC9948168","cross_references":{"pubmed":["36844536"],"doi":["10.1021/acsomega.2c07793"]}}